Investigating a new treatment for spinal cord injuries using a specific antibody therapy.
Official title: Preclinical Toxicology Study of Intrathecal VersaMab-101 for spinal cord injury treatment
Funded at Versapeutics INC · NIH-10821556 · Data updated 2026-11-12
This study is testing a new treatment called VersaMab-101 to help people with spinal cord injuries by encouraging the growth of damaged nerve cells and improving their recovery.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versapeutics INC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | April 1, 2022 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,430,030 |
| NIH project number | 2R44NS127712-02 |
| Project ID | NIH-10821556 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have experienced acute spinal cord injuries.
✕Less likely to help
Patients with chronic spinal cord injuries or those under 21 years old may not benefit from this research.
What this research studies
This research focuses on developing a novel therapy for spinal cord injuries (SCI) using an antibody called VersaMab-101. The approach aims to promote the regeneration of damaged nerve cells by overcoming barriers that prevent axon growth at the injury site. By targeting specific interactions that inhibit recovery, the therapy seeks to restore neural circuits and improve functional outcomes for patients. The study will involve preclinical testing to evaluate the safety and effectiveness of this treatment before it can be considered for human trials.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly improves recovery and quality of life for individuals with spinal cord injuries.
How similar studies have gone: While there have been various approaches to spinal cord injury treatment, this specific method using antibody therapy is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Versapeutics INC
San Diego, United States Active
Researchers
- Principal investigator: Sun, Miao — Versapeutics INC
- Study coordinator: Sun, Miao
Related research
Other NIH-funded projects on the same topics.
-
Corticospinal neurons and recovery of precise forelimb movement after spinal cord injury
This project studies how spine injuries change brain circuits and whether targeted rehabilitation helps restore precise forelimb movement.
-
How baclofen and spinal cord stimulation interact in people with spinal cord injury
This study looks at how a common antispasmodic medicine (baclofen) works together with spinal cord stimulation in people who have spinal cord injuries and live with spasticity.
-
Targeting spinal cord inflammation with a new HuR inhibitor to help SCI patients
A new treatment approach uses a small molecule to block a brain-spinal inflammation regulator (HuR) that drives harmful inflammation after spinal cord injury, aiming to lessen damage and pain for people with SCI.
-
From Neural Control of Movement to Treatments for Spinal Cord Injury
A patient-focused project aims to translate how brain signals control movement after spinal cord injury into new treatments that improve muscle function and reduce spasticity.
-
Polaris: a compact system to help motor recovery after spinal cord injury and stroke
A new, easy-to-use device called Polaris may help people with spinal cord injury, stroke, or other chronic conditions regain movement by guiding a specialized reflex-based therapy.
-
Predicting and Preventing Chronic Aspiration After Traumatic Cervical Spinal Cord Injury
This project looks at swallowing problems and chronic aspiration in adults with traumatic neck spine injuries to find patterns that could prevent serious lung complications.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.